You are here: Industry Insights > NSCLC

News List

AstraZeneca’s Imfinzi fails to meet endpoint in Stage IV NSCLC pharmaceutical-technology
August 22, 2019
AstraZeneca has announced that Imfinzi (durvalumab), combined with tremelimumab, failed to achieve its primary endpoint in the Phase III NEPTUNE trial of patients with previously-untreated Stage IV non-small cell lung cancer (NSCLC).
FDA Approves Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors drugs
August 16, 2019
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive...
TAGRISSO Shows Improved Overall Survival in Trial for NSCLC americanpharmaceuticalreview
August 12, 2019
AstraZeneca announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or ...
BMS’ Opdivo fails to meet primary endpoint in NSCLC pharmaceutical-technology
July 26, 2019
Bristol-Myers Squibb (BMS) has announced that its immunotherapy Opvido (nivolumab) plus chemotherapy failed to meet its primary endpoint of overall survival (OS) in the Phase III CheckMate-227 trial of patients with first-line non-squamous non-small cell
Biomarck Announces Positive Results from NSCLC Study contractpharma
July 12, 2019
Statistical significance was achieved in improvement of Overall Response Rate in the in the BIO-11006/SOC group.
Cardiac Radiation Dose in NSCLC Predicts Mortality, Cardiac AEs drugs
June 17, 2019
Cardiac Radiation Dose in NSCLC Predicts Mortality, Cardiac AEs.
How are the First Lung Cancer Patients Treated with Opdivo 4.5 Years Later? PharmaSources/Yefenghong
April 29, 2019
Since Opdivo was approved, it has started its unbelievable road, and has so far been approved 17 indications by the FDA.
EC approves Pfizer’s NSCLC drug Vizimpro pharmaceutical-technology
April 23, 2019
EC approves Pfizer’s NSCLC drug Vizimpro
FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC drugs
April 18, 2019
FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC.
FDA expands first-line NSCLC label for Merck & Co.'s Keytruda firstwordpharma
April 12, 2019
FDA expands first-line NSCLC label for Merck & Co.'s Keytruda.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page